Equities Analysts Set Expectations for CRDL FY2028 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities researchers at HC Wainwright upped their FY2028 earnings estimates for shares of Cardiol Therapeutics in a research note issued on Friday, August 15th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.51 per share for the year, up from their previous estimate of $0.40. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2029 earnings at $1.05 EPS.

Cardiol Therapeutics Price Performance

NASDAQ:CRDL opened at $1.22 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.26 and a quick ratio of 3.26. The firm has a market cap of $102.13 million, a price-to-earnings ratio of -3.59 and a beta of 1.05. The company has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.20. Cardiol Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.63.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04.

Hedge Funds Weigh In On Cardiol Therapeutics

Several institutional investors have recently made changes to their positions in CRDL. Envestnet Asset Management Inc. purchased a new position in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $398,000. Cetera Investment Advisers purchased a new position in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $56,000. PVG Asset Management Corp purchased a new position in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $624,000. Lion Street Advisors LLC increased its holdings in shares of Cardiol Therapeutics by 8.5% during the 1st quarter. Lion Street Advisors LLC now owns 333,725 shares of the company’s stock valued at $318,000 after purchasing an additional 26,059 shares in the last quarter. Finally, Tejara Capital Ltd increased its holdings in shares of Cardiol Therapeutics by 2.6% during the 1st quarter. Tejara Capital Ltd now owns 3,194,990 shares of the company’s stock valued at $3,099,000 after purchasing an additional 79,553 shares in the last quarter. 12.49% of the stock is owned by hedge funds and other institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.